Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01745848 · ClinicalTrials.gov registry record · Phase 4
Roflumilast on Markers of Bone Metabolism and Endothelial Function in COPD
A Phase 4 study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 4
- Development phase
- 26
- Enrollment target
NCT01745848 is a Phase 4 study that has completed, run by University of Pittsburgh. The registered enrollment target is 26 participants.
The verdict
NCT01745848, a Phase 4 study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 26 participants
- Enrollment target
Study Summary
Our primary hypothesis is that Roflumilast (500 μcg, once daily) will significantly decrease surrogate markers of bone metabolism and early cardiovascular disease in individuals with moderate to severe airflow obstruction and a chronic bronchitis phenotype.
Interventions
- DRUG Roflumilast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2013-02 |
| Est. Completion | 2016-06-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01745848
The ClinicalTrials.gov registry entry for NCT01745848 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Roflumilast is the first listed.
NCT01745848 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01745848 about?
NCT01745848 is a clinical study titled "Roflumilast on Markers of Bone Metabolism and Endothelial Function in COPD". Our primary hypothesis is that Roflumilast (500 μcg, once daily) will significantly decrease surrogate markers of bone metabolism and early cardiovascular disease in individuals with moderate to severe airflow obstruction and a chronic bronchitis phenotype.
What is the current status of trial NCT01745848?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 26 participants. The study started on 2013-02. Estimated completion is 2016-06-30.
What interventions are being tested in trial NCT01745848?
The interventions under investigation include: Roflumilast (DRUG).
Who is sponsoring clinical trial NCT01745848?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.